GlaxoSmithKline | GSK - Gross Profit On Sales


GlaxoSmithKline reported GBP5.75B in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
AbbVie USD 12.54B 474M Mar/2026
Alcon AG USD 1.69B 175M Mar/2026
Almirall EUR 429.87M 180.02M Dec/2025
Amgen USD 6.89B 415M Dec/2025
argenx SE USD 1.18B 40.98M Mar/2026
AstraZeneca USD 12.61B 225M Mar/2026
Bayer EUR 6.94B 1.58B Dec/2025
Biogen USD 1.82B 169.5M Mar/2026
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Eli Lilly USD 15.92B 1.33B Dec/2025
Fresenius EUR 1.51B 214M Dec/2025
Fresenius Medical Care EUR 1.18B 210M Mar/2026
Genmab DKK 977M 13M Dec/2025
Gilead Sciences USD 5.52B 791M Mar/2026
GlaxoSmithKline GBP 5.75B 429M Mar/2026
Glaxosmithkline GBP 8.75B 2.92B Sep/2025
GRIFOLS EUR 686.84M 56.95M Dec/2025
Hikma Pharmaceutical USD 362.5M 329.5M Jun/2025
Lakefront Biotherapeutics EUR 1.68M 898.68M Mar/2026
Lonza CHF 1.29B 248M Jun/2025
Merck EUR 3.07B 104M Mar/2026
Merck USD 10.85B 2.57B Dec/2025
Novartis USD 10.07B 184M Mar/2026
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Orion EUR 254M 254.7M Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
Philips EUR 1.77B 522M Mar/2026
Recordati EUR 472.65M 40.24M Dec/2025
Regeneron Pharmaceuticals USD 2.94B 363.7M Mar/2026
Roche Holding CHF 22.09B 10.04B Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
Smith & Nephew USD 2.09B 117M Dec/2025
UCB EUR 3.19B 621M Dec/2025